News & Trends - Pharmaceuticals

New marker to pave the way for melanoma vaccine

Health Industry Hub | September 21, 2020 |
[Total: 1    Average: 5/5]

Pharma News: A collaborative study led by Monash University’s Biomedicine Discovery Institute and the Olivia Newton-John Cancer Research Institute (ONJCRI) has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma.

Despite all improvements in melanoma treatment, every five hours one Australian dies because of the lack of effective treatment. A promising new approach harnesses the body’s own immune system to detect and kill tumour cells, through recognition of small tumour specific protein fragments (peptides) that decorate the surface of the tumour cells.  The study, published in Cancer Immunology Research, a journal of the American Association for Cancer Research, has successfully identified thousands of peptides uniquely present on melanoma tumours that can be recognised by the immune system.

These observations have had an immediate clinical application, with the first clinical study on vaccination of melanoma patients using spliced peptides underway with collaborators at the Parker Institute for Cancer Immunotherapy, USA.

The study was co-led by Monash Biomedicine Discovery Institute’s Dr Pouya Faridi, Professor Anthony Purcell and Associate Professor Ralf Schittenhelm, and Drs Katherine Woods and Andreas Behren from the Olivia Newton John Cancer Institute.

“We considered how a melanoma tumour might ‘look’ to the human immune system, under different growth conditions. The sheer scope of melanoma peptides that we identified in this study, many of which have never been reported before, was both surprising and inspiring,” said Dr Woods.

Findings have shown that some of these melanoma peptide markers are generated from a process called splicing. In splicing, a protein is first cut into small pieces (peptides) and then two of these pieces are pasted together to make a “spliced peptide”. By identifying the exact spliced peptides, they can be synthesised outside of the body, then administered to patients to trigger the immune system into recognising and targeting tumours.

“The general goal of our study was to find new targets for melanoma treatment.  We were unaware of the existence, prevalence and importance of these unique spliced peptides or if they could be recognised by the immune system.  Now that we know they can, these peptides can be used as bait for the immune system to take action,” Dr Faridi said.

Dr Andreas Behren, Head Tumour Immunology Laboratory at ONJCRI said “Our finding, that we can successfully identify spliced melanoma peptides that are immunogenic across different patients, is very exciting.”

Professor Purcell notes “Based on these studies, spliced peptide antigens have moved from an immunological curiosity to a whole new class of actionable targets not just in melanoma but other cancers as well. Using Dr Faridi’s new workflow we have been able to shine a spotlight on this previously ignored class of peptides opening up a previously untapped resource for immunotherapy and cancer vaccination. Indeed, the ubiquitous nature of this splicing process point towards this class of antigens playing roles in infectious disease, autoimmunity and allergy.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Marketing & Strategy

PRIME Award 2020 winners announced

Health Industry Hub | September 24, 2020 |

The first ever virtual PRIME Awards saw the best and brightest healthcare communications work recognised in the pharmaceutical and life […]

More


News & Trends - Pharmaceuticals

Pharma News - Australia’s first Antimicrobial Resistance Network to combat global health threat

Australia’s first Antimicrobial Resistance Network to combat global health threat

Health Industry Hub | September 24, 2020 |

Please log in to Health Industry Hub to view this content in the News menu → Pharmaceuticals sub-menu.

More


News & Trends - Medical Technology

MedTech News - Companies playing an important role in the robot-assisted surgery market

Companies playing an important role in the robot-assisted surgery market

Health Industry Hub | September 23, 2020 |

MedTech News: The market for surgical robots is expected to grow from USD 6.7 billion in 2020 to USD 11.8 […]

More


News & Trends - Pharmaceuticals

Pharma News - Roche acquires Inflazome co-founded by local researcher

Roche acquires Inflazome co-founded by local researcher

Health Industry Hub | September 23, 2020 |

Please log in to Health Industry Hub to view this content in the News menu → Pharmaceuticals sub-menu.

More